Patent US4452800A successfully refreshed from Google Patents.
US4452800A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Salts of 3(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one and their use in treating chronic obstructive lung diseases
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1982-04-26
•
Granted: 1984-06-05
•
Expires: 2002-04-26
Abstract
Abstract There are disclosed certain alkali metal, alkaline earth metal, amine and amino acid salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one which, unlike the parent compound, are useful for orally treating chronic obstructive lung diseases such as asthma, bronchitis and the like.
Inventors
- 👤 Margaret H. Sherlock
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 08:37
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04; A; A61; A61P; A61P11/00; A61P37/00; A61P37/08; C07D241/00; C07D241/02; C07D241/10; C07D241/14; C07D241/24; C07D241/26
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
19 words
A compound selected from the group consisting of calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one.
Claim 2
Dependent Claim
19 words
A compound selected from the group consisting of calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one.
Claim 3
Dependent Claim
10 words
The compound of claim 1 wherein the salt is calcium.
Claim 4
Dependent Claim
10 words
The compound of claim 1 wherein the salt is ethanolamine.
Claim 5
Dependent Claim
10 words
The compound of claim 1 wherein the salt is N-methylglucamine.
Claim 6
Dependent Claim
10 words
The compound of claim 1 wherein the salt is diethanolamine.
Claim 7
Dependent Claim
10 words
The compound of claim 1 wherein the salt is ethylenediamine.
Claim 8
Dependent Claim
32 words
A compound which is physically in the form of a dry solid material, selected from the group consisting of sodium, potassium, calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one.
Claim 9
Dependent Claim
32 words
A compound which is physically in the form of a dry solid material, selected from the group consisting of sodium, potassium, calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one.
Claim 10
Dependent Claim
10 words
The compound of claim 7, wherein the salt is sodium.
Claim 11
Dependent Claim
8 words
The monohydrate of the compound of claim 8.
Claim 12
Dependent Claim
10 words
The compound of claim 7 wherein the salt is potassium.
Claim 13
Dependent Claim
10 words
The compound of claim 7 wherein the salt is calcium.
Claim 14
Dependent Claim
10 words
The compound of claim 7 wherein the salt is ethanolamine.
Claim 15
Dependent Claim
10 words
The compound of claim 7 wherein the salt is N-methylglucamine.
Claim 16
Dependent Claim
10 words
The compound of claim 7 wherein the salt is diethanolamine.
Claim 17
Dependent Claim
10 words
The compound of claim 7 wherein the salt is ethylenediamine.
Claim 18
Dependent Claim
44 words
A pharmaceutical composition for treating chronic obstructive lung diseases which comprises an effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one, together with a pharmaceutically acceptable carrier.
Claim 19
Dependent Claim
44 words
A pharmaceutical composition for treating chronic obstructive lung diseases which comprises an effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one, together with a pharmaceutically acceptable carrier.
Claim 20
Dependent Claim
43 words
A pharmaceutical composition for treating allergic reactions which comprises an anti-allergy effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one, together with a pharmaceutically acceptable carrier.
Claim 21
Dependent Claim
43 words
A pharmaceutical composition for treating allergic reactions which comprises an anti-allergy effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one, together with a pharmaceutically acceptable carrier.
Claim 22
Dependent Claim
42 words
A pharmaceutical composition for treating asthma which comprises an anti-asthma effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one, together with a pharmaceutically acceptable carrier.
Claim 23
Dependent Claim
42 words
A pharmaceutical composition for treating asthma which comprises an anti-asthma effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridine-2(1H)-one, together with a pharmaceutically acceptable carrier.
Claim 24
Dependent Claim
9 words
A composition of claim 16 suitable for oral administration.
Claim 25
Dependent Claim
9 words
A composition of claim 17 suitable for oral administration.
Claim 26
Dependent Claim
9 words
A composition of claim 18 suitable for oral administration.
Claim 27
Dependent Claim
15 words
The composition defined in claim 16 wherein the compound is the sodium salt of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2-(1H)-one.
Claim 28
Dependent Claim
15 words
The composition defined in claim 17 wherein the compound is the sodium salt of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one.
Claim 29
Dependent Claim
15 words
The composition defined in claim 18 wherein the compound is the sodium salt of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one.
Claim 30
Independent Claim
44 words
A method of treating chronic obstructive lung diseases which comprises administering an effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2-(1H)-one to a patient having said disease.
Claim 31
Independent Claim
44 words
A method of treating chronic obstructive lung diseases which comprises administering an effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methylglucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2-(1H)-one to a patient having said disease.
Claim 32
Independent Claim
44 words
A method of treating allergic diseases which comprises administering an anti-allergy effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methyl-glucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one to a patient having an allergic disease.
Claim 33
Independent Claim
44 words
A method of treating allergic diseases which comprises administering an anti-allergy effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methyl-glucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one to a patient having an allergic disease.
Claim 34
Independent Claim
41 words
A method of treating asthma which comprises administering an anti-asthma effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methyl-glucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one to a patient having asthma.
Claim 35
Independent Claim
41 words
A method of treating asthma which comprises administering an anti-asthma effective amount of a compound selected from the group consisting of sodium, sodium monohydrate, potassium, calcium, ethanolamine, N-methyl-glucamine, diethanolamine, ethylenediamine, trishydroxyethyl-methylamine and lysine salts of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one to a patient having asthma.
Claim 36
Dependent Claim
15 words
The method defined in claim 25 wherein the compound is the sodium salt of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one.
Claim 37
Dependent Claim
15 words
The method defined in claim 26 wherein the compound is the sodium salt of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one.
Claim 38
Dependent Claim
15 words
The method defined in claim 27 wherein the compound is the sodium salt of 3-(n-butyl)-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one.
References Cited (Backward Citations)
JPS52116495A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-06-05 | 1987-12-05 | 1988-06-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-06-05 | 1991-12-05 | 1992-06-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-06-05 | 1995-12-05 | 1996-06-05 | $7700.00 | Window Closed / Lapsed |